Questions for the Intermune (ITMN) Conference Call
So after the rebuff earlier this year from the FDA for Intermune’s lead product pirfenidone, the company will hold a conference call to discuss its quarterly progress. Since there has not been much clarity on how the company plans to come forward I expect there to be several questions on the topic of moving the pirfenidone development program forward.
The company held a pretty comprehensive conference call after the FDA issued the company a complete response letter earlier this year, but I think investors are going to want a thorough update on how the company plans to move the drug ahead. So on the next page are some questions that I am looking for the company to be asked and be prepared to answer in relation to the development of their lead product pirfenidone, also remember to click an ad if the article was helpful.
cont’d on next page
Twitter
